BTTAA
目录号 : GC30061BTTAA是一种Cu(I)-稳定配体,能够很好地与泛素Glu18AzF反应。
Cas No.:1334179-85-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
BTTAA is a Cu(I)-stabilizing ligand, whch performs potently with ubiquitin Glu18AzF.
BTTAA is a Cu(I)-stabilizing ligand. Using the Glu18AzF mutant of ubiquitin as a model system with C3-Tm3+ and C4-Tm3+, Cu-BTTAA performs significantly better as a catalyst than Cu-THPTA or Cu-TBTA. BTTAA proves to perform much better than THPTA (tris[(1-hydroxy-propyl-1H-1,2,3-triazol-4-yl)methyl]amine) or TBTA (tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine)[1].
[1]. Loh CT et al. Lanthanide tags for site-specific ligation to an unnatural amino acid and generation of pseudocontact shifts inproteins. Bioconjug Chem. 2013 Feb 20;24(2):260-8.
BTTAA 是一种稳定 Cu(I) 的配体,与泛素 Glu18AzF 一起有效发挥作用。
BTTAA 是一种稳定 Cu(I) 的配体。使用泛素的 Glu18AzF 突变体作为具有 C3-Tm3+ 和 C4-Tm3+ 的模型系统,Cu-BTTAA 作为催化剂的性能明显优于 Cu-THPTA 或 Cu-TBTA。 BTTAA 证明比 THPTA(三[(1-羟基丙基-1H-1,2,3-三唑-4-基)甲基]胺)或 TBTA(三[(1-苄基-1H-1, 2,3-三唑-4-基)甲基]胺)[1].
[1]. Loh CT 等人。用于与非天然氨基酸进行位点特异性连接并在蛋白质中产生假接触位移的镧系元素标签。生物结合化学。 2013 年 2 月 20 日;24(2):260-8。
Cas No. | 1334179-85-9 | SDF | |
Canonical SMILES | O=C(O)CN1N=NC(CN(CC2=CN(C(C)(C)C)N=N2)CC3=CN(C(C)(C)C)N=N3)=C1 | ||
分子式 | C19H30N10O2 | 分子量 | 430.51 |
溶解度 | Water : 5 mg/mL (11.61 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3228 mL | 11.6141 mL | 23.2283 mL |
5 mM | 0.4646 mL | 2.3228 mL | 4.6457 mL |
10 mM | 0.2323 mL | 1.1614 mL | 2.3228 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Lanthanide tags for site-specific ligation to an unnatural amino acid and generation of pseudocontact shifts in proteins
Bioconjug Chem.2013 Feb 20;24(2):260-8.PMID: 23294422DOI:10.1021/bc300631z
Pseudocontact shifts (PCS) from paramagnetic lanthanide ions present powerful long-range structural restraints for structural biology by NMR spectroscopy, but site-specific tagging of proteins with lanthanides remains a challenge, as most of the available lanthanide tags require proteins with single cysteine residues. We show that cyclen-based paramagnetic lanthanide tags can be attached to proteins in a site-specific manner by Cu(I)-catalyzed azide-alkyne cycloaddition to a genetically encoded p-azido-l-phenylalanine residue with a tether that proved sufficiently short and rigid for the observation of PCSs in several proteins. Despite the sterically demanding conditions associated with bulky tags and reactions close to the protein surface, ligation yields consistently above 50% and approaching 100% were obtained with the help of the Cu(I)-stabilizing ligand BTTAA. The yields were high independent of the presence of cysteine residues, thereby avoiding the need for cysteine mutations associated with conventional lanthanide-tagging strategies.
Copper-Triggered Bioorthogonal Cleavage Reactions for Reversible Protein and Cell Surface Modifications
J Am Chem Soc. 2019 Oct 30;141(43):17133-17141. PMID: 31580665DOI:10.1021/jacs.9b05833
Temporal and reversible control over protein and cell conjugations holds great potential for traceless release of antibody-drug conjugates (ADCs) on tumor sites as well as on-demand altering or removal of targeting elements on cell surface. We herein developed a bioorthogonal and traceless releasable reaction on proteins and intact cells to fulfill such purposes. A systematic survey of transition metals in catalyzing the bioorthogonal cleavage reactions revealed that copper complexes such as Cu(I)-BTTAA and dual-substituted propargyl (dsPra) or propargyloxycarbonyl (dsProc) moieties offered a bioorthogonal releasable pair for reversible blockage and rescue of primary amines and phenol alcohols on small molecule drugs, protein side chains, as well as intact cell surface. For proof-of-concept, we employed such Cu(I)-BTTAA/dsProc and Cu(I)-BTTAA/dsPra pairs as a "traceless linker" strategy to construct cleavable ADCs to unleash cytotoxic compounds on cancer cells in situ and as a "reversible modification" strategy for cell surface engineering. Furthermore, by coupling with the genetic code expansion strategy, we site-specifically modulated ligand-receptor interactions on live cell membranes. Together, our work expanded the transition-metal-mediated bioorthogonal cleavage tool kit from terminal decaging to internal-linker breakage, which offered a temporal and reversible conjugation strategy on therapeutic proteins and cells.